Drug intelligence / Profile preview

LP-306

Development stage: Unknown
Lead developer: Lara Pharm
Modality: Small Molecules
Administration: Inhalation

Overview

LP-306 is a synthetic formulation of Tetrahydrocannabinol (THC) administered via an inhaler. Developed by Lara Pharm, it is intended as a pharmaceutical substitute for medical marijuana. THC, the primary psychoactive component of cannabis, primarily exerts its effects by acting as a partial agonist on cannabinoid receptors, particularly CB1 and CB2, influencing neurotransmission and immune function.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on LP-306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-306.

Explore the full profile